What Hemostod does

HemostOD SA is a Swiss preclinical biotech company founded in 2020 and headquartered at the EPFL Innovation Park in St-Sulpice (Lausanne), Switzerland. It is developing a proprietary platform to engineer and manufacture universal, HLA-low human blood platelets on demand from immortalized hematopoietic stem cells, targeting patients with thrombocytopenia, particularly those with or at risk of HLA immune-refractoriness for whom standard donor platelets are ineffective. The company explicitly positions its first clinical trial for 2027 and currently has no commercial products, revenue, or paying customers.

The core technology integrates four IP-protected steps: (1) immortalization of hematopoietic progenitor cells from a single donor to create a stable cell line, (2) cell engineering to introduce custom features — branded as CAR-PLT — enabling shielded delivery of miRNA/siRNA or proteins to specific target tissues, (3) differentiation into a practically unlimited source of megakaryocytes, and (4) ex-vivo generation of platelets via advanced microfluidic bioreactor technology that fragments megakaryocytes into large quantities of homogeneous platelets within hours. A 1-liter proof-of-concept scale has been demonstrated. Beyond the lead transfusion program, the platform supports adjacent applications including tissue-targeted cargo delivery, regenerative medicine (wound healing, anti-inflammatory and immunomodulating uses), and platelet lysate for therapeutic stem cell culture.

The business model is preclinical R&D-oriented with no current revenue: the company has raised approximately CHF 8.65 million to date through a mix of equity seed rounds (CHF 1.7M in 2021 led by Orenok Holdings, CHF 4.3M seed extension in 2025 co-led by Polytech Ventures and Orenok Holdings), non-dilutive Swiss public grants (Venture Kick CHF 50K total, Innosuisse CHF 2M in 2026), and FIT Tech loans (CHF 100K seed in 2022, CHF 500K growth in 2024). Future revenue is expected to derive from one-time licensing or product sales of universal platelets to hospitals, transfusion centers, and clinical facilities once regulatory approval is obtained. GTM is enterprise field sales targeting institutional healthcare buyers, supported by strategic co-development partnerships with the Swiss Biotech Center (pre-industrialization) and Interregional Blood Transfusion SRC (in vitro platelet production, quality, storage, and distribution). Customer segments explicitly identified include thrombocytopenia patients (primary), tissue-targeted drug delivery developers, regenerative medicine, and therapeutic stem cell culture users.

Name

Hemostod

Legal name

HemostOD SA

Website

https://hemostod.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

HemostOD is a Swiss preclinical biotech engineering universal HLA-low platelets from immortalized hematopoietic stem cells via a proprietary microfluidic bioreactor platform, targeting thrombocytopenia patients with HLA immune-refractoriness, with first clinical trials planned for 2027.

Ownership category

akta.pro rank

Product category

Transfusion Medicine Biologics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)

akta.pro secondary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

Keywords

• Engineered platelets
• Platelet manufacturing
• Transfusion medicine
• Cell therapy biologics
• Regenerative medicine

Headquarters

HQ city

Lausanne

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Universal platelets for transfusion: Pre-revenue preclinical biotech company developing universal engineered platelets (HLA-low) for treatment of thrombocytopenia patients. Expected first clinical trial in 2027. Revenue model will likely be prescription/product sales to hospitals and transfusion centers upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

HemostOD develops and manufactures universal platelets on-demand from engineered hematopoietic stem cells using a proprietary IP-protected platform. The process combines molecular and cell biology techniques to build stable megakaryocytic cell lines, followed by microfluidic bioreactor technology to fragment megakaryocytes into platelets in hours. Core products include universal HLA-low platelets for transfusion medicine (addressing thrombocytopenia and HLA immune-refractoriness), CAR-PLT engineered platelets for tissue-targeted therapeutic cargo delivery, and platelet lysate for therapeutic stem cell culture.

Product overview

HemostOD is a Swiss preclinical biotech company developing a portfolio of engineered blood platelet products based on its proprietary manufacturing platform. The core offering consists of universal HLA-low platelets for transfusion medicine to address thrombocytopenia and platelet shortages. The platform also enables CAR-PLT™ technology for tissue-targeted delivery of therapeutic cargo (miRNA/siRNA/proteins), and platelet lysate for therapeutic stem cell culture. The integrated platform combines immortalization of hematopoietic stem cells, cell engineering, differentiation into megakaryocytes, and ex-vivo platelet generation using microfluidic bioreactor technologies.

Differentiator

Problem solved

Functional benefit

Products and services

• Universal Platelets (HLA-low) Engineered universal human blood platelets for transfusion medicine, designed to address platelet shortages worldwide. Platelets are engineered to be HLA-low to reduce immune-refractoriness in patients undergoing treatment for thrombocytopenia, including those who cannot receive standard donor platelets.
• CAR-PLT (Engineered Platelet for Targeted Cargo Delivery) Engineered platelets with custom surface features enabling shielded delivery of therapeutic cargo such as miRNA, siRNA, or proteins to specific target tissues. Designed for biotech and pharmaceutical partners developing targeted therapeutics.
• Platelet Lysate Platelet lysate produced from HemostOD's universal platelets, intended to boost cell proliferation in therapeutic stem cell culture applications and to serve regenerative medicine research and cell therapy developers.

Quantifiable outcome

• Production scale of 1 liter proof-of-concept achieved
• +1 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Interregional Blood Transfusion SRCcoreStrategic or Co-development Partner · 14 May 2024Partnership with the biggest Swiss blood transfusion service to collaborate on in vitro platelet production. The collaboration empowers development from bioreactor to patients, benefiting from IBT's expertise in transfusion medicine, platelet knowledge, and blood component processing, quality control, storage and distribution. First clinical trial targeted for 2027.
• EIT HealthminorStrategic or Co-development Partner · 4 November 2023Recognition and entry into EIT Health's Gold Track Programme, providing access to mentorship, funding opportunities, and network of industry experts across Europe. Validates innovative approach to platelet manufacturing and positions company for accelerated growth in European healthcare market.
• Swiss Biotech CentercoreStrategic or Co-development Partner · 2 April 2023Partnership with Swiss Biotech Center to pre-industrialize HemostOD's technology. The partnership provides access to solid expertise and state-of-the-art infrastructure in bioprocess engineering to accelerate R&D efforts towards clinical application.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Platelet BioGenesis: Massachusetts-based biotech developing iPSC-derived platelets for transfusion. Direct competitor to HemostOD in the on-demand, off-the-shelf engineered platelet space, targeting the same HLA-refractory and platelet shortage markets.
• Cellphire Therapeutics: Clinical-stage biotech developing platelet-derived hemostatic products, including a lyophilized platelet candidate. Comparable to HemostOD in producing platelet-based products for bleeding and thrombocytopenia indications, with a different shelf-life-stabilization approach.
• Velico Medical: Developer of spray-dried and storage-extended platelet and plasma technologies to address platelet shelf-life and supply constraints. Adjacent to HemostOD in solving the platelet supply problem but using a donor-platelet preservation approach rather than cell-based manufacturing.

Broad incumbents

• Cerus Corporation: Commercial-stage company whose INTERCEPT Blood System enables pathogen inactivation of platelets and other blood components. Broad incumbent in platelet transfusion safety whose installed base at blood centers represents both a potential competitive moat and partnership channel for HemostOD's universal platelets.
• Grifols: Global plasma-derived therapies company with a large blood products franchise including platelets and transfusion medicine solutions. Broad incumbent in the broader blood/plasma product market relevant to HemostOD's eventual commercial channel.
• Octapharma: One of the world's largest privately held plasma product manufacturers, with established hospital and transfusion center distribution networks. Comparable to HemostOD as a broad incumbent in blood-derived therapeutics with the distribution scale HemostOD will need post-approval.
• CSL Behring: Global leader in plasma-derived and recombinant coagulation therapies (including coagulation factor products for bleeding disorders). Broad incumbent whose hospital channel and regulatory infrastructure are analogous to those HemostOD will need for commercial-scale platelet distribution.
• Takeda Pharmaceutical (Shire Hematology franchise): Major biopharmaceutical company with a hematology franchise including plasma-derived and recombinant therapies for rare bleeding and platelet disorders. Broad incumbent providing a comparable regulatory, commercial, and clinical-development benchmark for HemostOD's transfusion medicine pipeline.

Emerging players

• Pluri (formerly Pluristem Therapeutics): Clinical-stage cell therapy company developing placenta-derived allogeneic cell therapies for hematology and regenerative medicine indications. Comparable to HemostOD as an emerging allogeneic cell therapy developer targeting hematological indications, with overlapping manufacturing scale-up challenges.
• CytoPlex: Early-stage company working on engineered platelet-like particles or cell-derived hemostatic products. Comparable as an emerging player addressing the platelet supply/function gap using engineered cell-based approaches that overlap with HemostOD's microfluidic production platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/hemostod

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hemostod